Clinical trial intelligence powered by machine learning.
FDA approval probability predictions for 475,000+ drug programs from 35+ data sources.
Built for biotech investors, analysts, and portfolio managers.
Featured Insight
Oncology programs with Breakthrough Therapy designation show 2.4x higher approval rates.
475K+
Drug Programs Scored
104
Predictive Features
96.8%
Prediction Accuracy (AUC)
35+
Data Sources, Updated Daily
Ingest
We pull data daily from 35+ public sources — FDA filings, ClinicalTrials.gov, SEC EDGAR, patent databases, medical journals, and more.
Score
Two XGBoost models score every active drug program for FDA approval probability using 100+ features, with temporal validation to prevent leakage.
Analyze
You screen, filter, and rank programs by POS, pipeline NPV, catalyst proximity, or short-alpha signals to find investment-relevant opportunities.
Net Alpha Screen
Risk-adjusted pipeline NPV minus patent-cliff erosion, ranked against market cap. The flagship view — pipeline value vs loss of exclusivity, net.
Per-Drug POS Scores
Every drug program scored individually with probability of FDA approval, plus a SHAP-style breakdown of the features driving each prediction.
Catalyst Intelligence
Upcoming Phase 2/3 readouts, PDUFA dates, and AdCom meetings, ranked by proximity-weighted NPV so near-term events get the attention they deserve.
Drug Screener
Filter 475K+ programs by POS, phase, FDA designations, therapeutic area, and clinical trial characteristics. Inline tooltips on every filter.
AdCom Intelligence
FDA advisory committee member profiling. Voting patterns, industry payments, academic credentials, and predicted panel outcomes.
Options & Short Alpha
ATM implied volatility, IV rank, put/call ratios, and a composite short-alpha score combining pipeline weakness, short interest, and cash runway.
Competitive & Regulatory
Drug-vs-drug comparisons across indications, FDA action tracking, and cross-agency approvals (FDA, EMA, PMDA).
Score Simulator
Toggle features (designations, trial design, endpoints) and see POS change in real time. Shareable via URL — useful for investor memos.
Two XGBoost models (early-stage + late-stage), 104 features, temporal validation. Prediction accuracy 0.968 AUC without label-leaky features — materially above the published industry benchmark.